|The AmeriKat is no stranger to hissing|
when she thinks change is needed...or if she is hungry
Angiomax patents' life span cut short by CAFC: As the Medicines Company found out a few days ago, sometimes legal certainty can be a bad thing. The Court of Appeals for the Federal Circuit (CAFC) held that Hospira's generic version of The Medicines Company's anticlotting drug bivalirudin, sold under the brand name Angiomax, was not infringing. Angiomax accounts for almost 83% of its total revenues in the US in 2014. The CAFC overturned the district court's earlier decision holding that The Medicine Company's patents protecting Angiomax were valid, but not infringed by Hospira's abbreviated new drug applications. The CAFC held that both patents subject to the dispute - US Patent No 7,582,727 and 7,598,343 - were invalid. The patents were due to expire in July 2028. In the lead up to the decision, Angiomax's revenues declined due, commentators suggested, to the legal uncertainty regarding its patent exclusivity. With the latest decision from the CAFC, sales were expected to further decline but following the decision, The Medicines Company's share price actually increased. This increase has stumped some analysts but others point to the company's recent FDA approvals including its approval for an authorized generic launch of Angiomax (in collaboration with Sandoz) (see link here).
|The jury award that took a bite out|
of Apple gets vacated by Judge Gilstrap
|The calm Pacific waters |
of the Trans-Pacific Partnership deal